Tagrisso shows ‘unprecedented’ disease free survival in lung cancer
The Phase III ADAURA trial showed treatment with Tagrisso after surgery with curative intent the the risk of disease recurrence or death by around 80%
Read More
Tag: ADAURA
- FDA approves new high dose Spinraza regimen for SMA
- Viridian reports positive results from elegrobart phase 3 trial
- Cure Parkinson’s convenes expert panel to assess £2 million combination therapy funding call
- Kygevvi approved in Europe as first treatment for TK2d
- Tozorakimab shows significant benefit in two major COPD trials
